Have Advances in Extracorporeal Removal Techniques Changed the Indications for Their Use in Poisonings?

Advances in Chronic Kidney Disease

Volumn 18, Issue 3, 2011, Pages 172-179

  Garlich, Fiona M ^a   Goldfarb, David S ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Carbamazepine; Hemoperfusion trends; Methotrexate; Overdose; Poisoning therapy; Poisons; Sorption detoxification methods; Valproic acid

Indexed keywords

ACTIVATED CARBON; BICARBONATE; CARBAMAZEPINE; CARNITINE; INSULIN; METHOTREXATE; MYOGLOBIN; TOXIN; VALPROIC ACID; VANCOMYCIN;

BLOOD CLOTTING DISORDER; BLOOD FLOW VELOCITY; CONTINUOUS HEMODIAFILTRATION; DIALYSIS; DIALYSIS MEMBRANE; DRUG DETOXIFICATION; DRUG INTOXICATION; HEMODIAFILTRATION; HEMODIALYSIS; HEMODYNAMICS; HEMOPERFUSION; HUMAN; HYPERAMMONEMIA; HYPOCALCEMIA; HYPOTHERMIA; INTOXICATION; LIVER TOXICITY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT INDICATION; ULTRAFILTRATION;

CARBAMAZEPINE; HEMODIAFILTRATION; HEMODYNAMICS; HEMOPERFUSION; HUMANS; INSULIN; MEMBRANES, ARTIFICIAL; METHOTREXATE; MYOGLOBIN; PERITONEAL DIALYSIS; POISONING; ULTRAFILTRATION; VALPROIC ACID; VANCOMYCIN;

EID: 79955400949     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2011.01.009     Document Type: Review

References (58)

1. Holubek W.J., Hoffman R.S., Goldfarb D.S., et al. Use of hemodialysis and hemoperfusion in poisoned patients. Kidney Int 2008, 74:1327-1334.
2. Fertel B.S., Nelson L.S., Goldfarb D.S. Extracorporeal removal techniques for the poisoned patient: a review for the intensivist. J Intensive Care Med 2010, 25:139-148.
3. Lameire N., Van B.W., Vanholder R. Did 20 years of technological innovations in hemodialysis contribute to better patient outcomes?. Clin J Am Soc Nephrol 2009, 4(suppl 1):S30-S40.
4. Palmer B.F. Effectiveness of hemodialysis in the extracorporeal therapy of phenobarbital overdose. Am J Kidney Dis 2000, 36:640-643.
5. Ambalavanan S., Rabetoy G.M., Cheung A.K. High-efficiency and high-flux hemodialysis. Atlas of Diseases of the Kidney, chap 3 1999, 3:1-3. Current Medicine, Philadelphia, PA, 10. W. Henrich, W. Bennet (Eds.).
6. Bowry S.K. Dialysis membranes today. Int J Artif Organs 2002, 25:447-460.
7. Cheung A.K., Levin N.W., Greene T., et al. Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. J Am Soc Nephrol 2003, 14:3251-3263.
8. Diamond S.M., Henrich W.L. Acetate dialysate versus bicarbonate dialysate: a continuing controversy. Am J Kidney Dis 1987, 9:3-11.
9. Luo F.J., Patel K.P., Marquez I.O., et al. Effect of increasing dialyzer mass transfer area coefficient and dialysate flow on clearance of protein-bound solutes: a pilot crossover trial. Am J Kidney Dis 2009, 53:1042-1049.
10. Thomas G., Jaber B.L. Convective therapies for removal of middle molecular weight uremic toxins in end-stage renal disease: a review of the evidence. Semin Dial 2009, 22:610-614.
11. van de P.A., Stolk L., Verhoeven M.A., et al. Successful treatment of acute phenobarbital intoxication by hemodiafiltration. Clin Toxicol (Phila) 2006, 44:93-94.
12. Kim Z., Goldfarb D.S. Continuous renal replacement therapy does not have a clear role in the treatment of poisoning. Nephron Clin Pract 2010, 115:c1-c6.
13. Shalkham A.S., Kirrane B.M., Hoffman R.S., et al. The availability and use of charcoal hemoperfusion in the treatment of poisoned patients. Am J Kidney Dis 2006, 48:239-241.
14. Litovitz T.L., Klein-Schwartz W., Caravati E.M., et al. 1998 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 1999, 17:435-487.
15. Bronstein A.C., Spyker D.A., Cantilena L.R., et al. 2006 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS). Clin Toxicol (Phila) 2007, 45:815-917.
16. Schuerer D.J., Brophy P.D., Maxvold N.J., et al. High-efficiency dialysis for carbamazepine overdose. J Toxicol Clin Toxicol 2000, 38:321-323.
17. Kielstein J.T., Schwarz A., Arnavaz A., et al. High-flux hemodialysis-an effective alternative to hemoperfusion in the treatment of carbamazepine intoxication. Clin Nephrol 2002, 57:484-486.
18. Dharnidharka V.R., Fennell R.S., Richard G.A. Extracorporeal removal of toxic valproic acid levels in children. Pediatr Nephrol 2002, 17:312-315.
19. Kane S.L., Constantiner M., Staubus A.E., et al. High-flux hemodialysis without hemoperfusion is effective in acute valproic acid overdose. Ann Pharmacother 2000, 34:1146-1151.
20. Johnson L.Z., Martinez I., Fernandez M.C., et al. Successful treatment of valproic acid overdose with hemodialysis. Am J Kidney Dis 1999, 33:786-789.
21. Fertel B.S., Nelson L.S., Goldfarb D.S. The underutilization of hemodialysis in patients with salicylate poisoning. Kidney Int 2009, 75:1349-1353.
22. Akil I.O., Mir S. Hemodiafiltration for vancomycin overdose in a patient with end-stage renal failure. Pediatr Nephrol 2001, 16:1019-1021.
23. Miner L.J., Faix R.G. Large vancomycin overdose in two premature infants with minimal toxicity. Am J Perinatol 2004, 21:433-438.
24. Goebel J., Ananth M., Lewy J.E. Hemodiafiltration for vancomycin overdose in a neonate with end-stage renal failure. Pediatr Nephrol 1999, 13:423-425.
25. Mellor J.A., Kingdom J., Cafferkey M., et al. Vancomycin toxicity: a prospective study. J Antimicrob Chemother 1985, 15:773-780.
26. Rybak M.J., Albrecht L.M., Boike S.C., et al. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990, 25:679-687.
27. Bunchman T.E., Valentini R.P., Gardner J., et al. Treatment of vancomycin overdose using high-efficiency dialysis membranes. Pediatr Nephrol 1999, 13:773-774.
28. Quale J.M., O'Halloran J.J., DeVincenzo N., et al. Removal of vancomycin by high-flux hemodialysis membranes. Antimicrob Agents Chemother 1992, 36:1424-1426.
29. Panzarino V.M., Feldstein T.J., Kashtan C.E. Charcoal hemoperfusion in a child with vancomycin overdose and chronic renal failure. Pediatr Nephrol 1998, 12:63-64.
30. Doyon S. Anticonvulsants. Goldfrank's Toxicologic Emergencies 2011, 698-710. McGraw-Hill, New York, NY. L.S. Nelson, N.A. Lewin, M.A. Howland, R.S. Hoffman, L.R. Goldfrank, N.E. Flomenbaum (Eds.).
31. Apfelbaum J.D., Caravati E.M., Kerns W.P., et al. Cardiovascular effects of carbamazepine toxicity. Ann Emerg Med 1995, 25:631-635.
32. Hojer J., Malmlund H.O., Berg A. Clinical features in 28 consecutive cases of laboratory confirmed massive poisoning with carbamazepine alone. J Toxicol Clin Toxicol 1993, 31:449-458.
33. Winnicka R.I., Topacinski B., Szymczak W.M., et al. Carbamazepine poisoning: elimination kinetics and quantitative relationship with carbamazepine 10,11-epoxide. J Toxicol Clin Toxicol 2002, 40:759-765.
34. Brahmi N., Kouraichi N., Thabet H., et al. Influence of activated charcoal on the pharmacokinetics and the clinical features of carbamazepine poisoning. Am J Emerg Med 2006, 24:440-443.
35. Spiller H.A. Management of carbamazepine overdose. Pediatr Emerg Care 2001, 17:452-456.
36. Hooper W.D., Dubetz D.K., Bochner F., et al. Plasma protein binding of carbamazepine. Clin Pharmacol Ther 1975, 17:433-440.
37. Vree T.B., Janssen T.J., Hekster Y.A., et al. Clinical pharmacokinetics of carbamazepine and its epoxy and hydroxy metabolites in humans after an overdose. Ther Drug Monit 1986, 8:297-304.
38. Sztajnkrycer M.D. Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol 2002, 40:789-801.
39. Kay T.D., Playford H.R., Johnson D.W. Hemodialysis versus continuous veno-venous hemodiafiltration in the management of severe valproate overdose. Clin Nephrol 2003, 59:56-58.
40. Al A.Z., Yalamanchili P., Gonzalez E. Extracorporeal management of valproic acid toxicity: a case report and review of the literature. Semin Dial 2005, 18:62-66.
41. Saland J.M., Leavey P.J., Bash R.O., et al. Effective removal of methotrexate by high-flux hemodialysis. Pediatr Nephrol 2002, 17:825-829.
42. Wall S.M., Johansen M.J., Molony D.A., et al. Effective clearance of methotrexate using high-flux hemodialysis membranes. Am J Kidney Dis 1996, 28:846-854.
43. Widemann B.C., Balis F.M., Kempf-Bielack B., et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 2004, 100:2222-2232.
44. Green M.R., Chamberlain M.C. Renal dysfunction during and after high-dose methotrexate. Cancer Chemother Pharmacol 2009, 63:599-604.
45. Vilay A.M., Mueller B.A., Haines H., et al. Treatment of methotrexate intoxication with various modalities of continuous extracorporeal therapy and glucarpidase. Pharmacotherapy 2010, 30:111.
46. Chabner B.A., Allegra C.J., Curt G.A., et al. Polyglutamation of methotrexate. Is methotrexate a prodrug?. J Clin Invest 1985, 76:907-912.
47. Wang R.Y. Antineoplastics: methotrexate. Goldfrank's Toxicologic Emergencies 2011, 778-782. McGraw-Hill, New York, NY. L.S. Nelson, N.A. Lewin, M.A. Howland, R.S. Hoffman, L.R. Goldfrank, N.E. Flomenbaum (Eds.).
48. Bunchman TE, Ferris ME. Management of toxic ingestions with the use of renal replacement therapy. Pediatr Nephrol. In press.
49. Howell S.B., Blair H.E., Uren J., et al. Hemodialysis and enzymatic cleavage of methotrexate in man. Eur J Cancer 1978, 14:787-792.
50. Roberge R.J., Martin T.G., Delbridge T.R. Intentional massive insulin overdose: recognition and management. Ann Emerg Med 1993, 22:228-234.
51. Abe M., Kikuchi F., Kaizu K., et al. The influence of hemodialysis membranes on the plasma insulin level of diabetic patients on maintenance hemodialysis. Clin Nephrol 2008, 69:354-360.
52. Abe M., Kaizu K., Matsumoto K. Plasma insulin is removed by hemodialysis: evaluation of the relation between plasma insulin and glucose by using a dialysate with or without glucose. Ther Apher Dial 2007, 11:280-287.
53. Nieminen P., Mustonen A.M., Kirsi M. Increased plasma creatine kinase activities triggered by edible wild mushrooms. Food Chem Toxicol 2005, 43:133-138.
54. Zager R.A. Rhabdomyolysis and myohemoglobinuric acute renal failure. Kidney Int 1996, 49:314-326.
55. Hart P.M., Feinfeld D.A., Briscoe A.M., et al. The effect of renal failure and hemodialysis on serum and urine myoglobin. Clin Nephrol 1982, 18:141-143.
56. Nicolau D., Feng Y.S., Wu A.H., et al. Myoglobin clearance during continuous veno-venous hemofiltration with or without dialysis. Int J Artif Organs 1998, 21:205-209.
57. Ronco C. Extracorporeal therapies in acute rhabdomyolysis and myoglobin clearance. Crit Care 2005, 9:141-142.
58. Naka T., Jones D., Baldwin I., et al. Myoglobin clearance by super high-flux hemofiltration in a case of severe rhabdomyolysis: a case report. Crit Care 2005, 9:R90-R95.